Breaking News
Get 60% Off 0
Cyber Monday Deal: Up to 60% off InvestingPro
CLAIM SALE
Close

Medigene NA O.N. (MDG1k)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.106 0.000    0.00%
13:29:04 - Delayed Data. Currency in EUR
Type:  Equity
Market:  Germany
ISIN:  DE000A40ESG2 
WKN:  A40ESG
  • Volume: 27,063
  • Bid/Ask: 1.112 / 1.168
  • Day's Range: 1.102 - 1.156
Medigene 1.106 0.000 0.00%

Medigene NA O.N. Company Profile

 
Get an in-depth profile of Medigene NA O.N., including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

87

Equity Type

ORD

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company has research collaboration with WuXi Biologics to design and co-research TCR-guided T Cell engagers (TCR-TCEs) for the treatment of difficult-to-treat tumors. Medigene AG was founded in 1994 and is headquartered in Munich, Germany.

Contact Information

Address Lochhamer Strasse 11 Planegg/Martinsried
Munich, 82152
Germany
Phone 49 89 2000 330
Fax 49 89 2000 3329 20

Top Executives

Name Age Since Title
Frank Mathias 59 2008 Independent Member of the Supervisory Board
Antoinette Hiebeler-Hasner 63 2016 Independent Deputy Chairwomen of the Supervisory Board
Freda Stevenson - 2017 Member of Scientific Advisory Board
Anthony Man 67 2020 Independent Member of the Supervisory Board
Micha Drukker - 2017 Member of Scientific Advisory Board
Peter H. Krammer 56 2017 Member of Scientific Advisory Board
Jolanda de Vries - 2017 Member of Scientific Advisory Board
Lawrence E. Samelson - 2017 Member of Scientific Advisory Board
Ronald Scott 67 2017 Independent Member of the Supervisory Board
Ernst-Ludwig Winnacker 81 2016 Co-Founder & Chairman Scientific Advisory Board
Gerd Zettlmeissl 68 2017 Independent Chairman of the Supervisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MDG1k Comments

Write your thoughts about Medigene NA O.N.
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email